U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07729852) titled 'Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France' on July 16.
Brief Summary: This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple System Atrophy
Intervention:
DRUG: ATH434
ATH434 75 mg tablets administered orally twice daily (BID).
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Alterity Therapeutics
Published by ...